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Summary
 
Experimental leishmaniasis offers a well characterized model of T helper type 1 cell (Th1)-medi-
ated control of infection by an intracellular organism. Susceptible BALB/c mice aberrantly de-
velop Th2 cells in response to infection and are unable to control parasite dissemination. The
early CD4
 
1
 
 T cell response in these mice is oligoclonal and reflects the expansion of V
 
b
 
4/
V
 
a
 
8-bearing T cells in response to a single epitope from the parasite 
 
Leishmania
 
 homologue of
mammalian RACK1 (LACK) antigen. Interleukin 4 (IL-4) generated by these cells is believed
to direct the subsequent Th2 response. We used T cells from T cell receptor–transgenic mice
expressing such a V
 
b
 
4/V
 
a
 
8 receptor to characterize altered peptide ligands with similar affinity
for I-A
 
d
 
. Such altered ligands failed to activate IL-4 production from transgenic LACK-specific
T cells or following injection into BALB/c mice. Pretreatment of susceptible mice with altered
peptide ligands substantially altered the course of subsequent infection. The ability to confer a
healer phenotype on otherwise susceptible mice using altered peptides that differed by a single
amino acid suggests limited diversity in the endogenous T cell repertoire recognizing this antigen.
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L
 
eishmania major
 
 is a complex intracellular protozoan
parasite of macrophages in the vertebrate host that re-
quires a robust Th1 response for control of infection (re-
viewed in 1). Requirements for MHC class II molecules, T
cells, IFN-
 
g
 
, IL-12, and NOS2 have delineated a pathway
by which CD4
 
1
 
 T cells differentiate into Th1 effector cells
that activate macrophages and confer resistance to the dis-
ease. Among mice with I-A
 
d
 
 class II molecules, the CD4
 
1
 
T cell immune response is focused dominantly on a single
 
epitope from the parasite LACK
 
1
 
 antigen, which results
in oligoclonal expansion of cells bearing V
 
b
 
4/V
 
a
 
8 het-
erodimeric TCR in the regional lymph nodes (2, 3). The
dominant nature of this antigen was demonstrated using
TCR-transgenic mice that expressed a monoclonal 
 
ab
 
 T
cell repertoire to this epitope; such mice displayed remark-
able control over the organism, despite the absence of T
cells that recognize any parasite-specific antigens other than
the single epitope from LACK (4).
Unlike resistant strains of mice, BALB/c mice develop
aberrant Th2 responses after challenge with 
 
L. major
 
 and
sustain fatal disseminated disease. The early CD4
 
1
 
 T cell
response is also dominated by expansion of LACK-specific T
cells that express V
 
b
 
4/V
 
a
 
8 TCR. However, activation of
these cells results in the rapid production of IL-4 that drives
the subsequent Th2 response (5, 6). Deletion of LACK-
reactive cells, either through thymic expression of LACK as
a transgene (7) or superantigen-mediated deletion of V
 
b
 
4-
expressing CD4
 
1
 
 T cells (5), attenuated the early production
of IL-4 and promoted the differentiation of Th1 effector
cells that controlled disease in infected BALB/c mice. These
and other data have suggested a model whereby susceptibil-
ity to 
 
L. major
 
 in BALB strain mice is driven by a conflu-
ence of factors involving the inherent propensity to pro-
duce IL-4 after activation in the setting of an appropriately
sized precursor pool of LACK-reactive CD4
 
1
 
 T cells (8).
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Abbreviations used in this paper:
 
 ABLE, LACK T cell receptor–specific
transgenic; CDR3, complementarity determining region 3; LACK, 
 
Leish-
mania
 
 homologue of mammalian RACK1; RT, reverse transcriptase;
TCR-C
 
a
 
0
 
, T cell receptor constant region-
 
a
 
–deficient.
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The 
 
L. major
 
 model provides an opportunity to test
the plasticity of the wild-type CD4
 
1
 
 T cell repertoire in
susceptible mice. The conserved charge and length of the
peptide-interacting complementarity determining region 3
(CDR3) domain from LACK-reactive T cell hybridomas
suggested the observation that a single parasite antigen
served as the focus of their recognition (2). The constraints
on the entire LACK-reactive repertoire in the intact animal
remain unknown, however. We decided to indirectly test
such constraints by attempting to abrogate activation of
these cells in vivo using altered ligands. We demonstrate
substantial protection against disease in this system, suggest-
ing that identification of dominant antigens from organisms
can be used to target pathogenic T cells that mediate pro-
gressive disease in a highly specific manner.
 
Materials and Methods
 
Reagents.
 
The LACK
 
156–173
 
 peptide (ICFSPSLEHPIVVSG-
SWD), LACK-N164 and LACK-K164 mutant peptides with the
designated alterations of H at position 164, and the OVA
 
323–336
 
peptide (ISQAVHAAHAEINE) were synthesized on an Advanced
Chemtech Multiple Peptide Synthesizer. Peptides were purified
by reverse phase HPLC and their identities confirmed by analysis
with an LCQ mass spectrometer (Finnigan MAT).
The full length rLACK sequence was ligated downstream of a
hemagglutinin epitope, six histidine residues, and factor X cleav-
age site in the pET3a-
 
d
 
9 vector as described (5). A 41–amino acid
deletion construct (rLACK
 
D
 
41) that excised the LACK
 
156–173
 
epitope was created and expressed from the same vector as de-
scribed (5). rLACK-N164 and rLACK-K164 were produced by
site-directed mutagenesis of the nucleotide triplet at bp 684–686
from CAC (H) to AAC (N) or AAG (K), respectively, based
on codon usage in 
 
Leishmania
 
 (9). The XbaI/HindIII fragment
of rLACK (1,134 bp) was cloned into the pGEM11Zf(
 
2
 
) vec-
tor (Promega). Mutations were generated with the PCR-based
QuikChange™ site-directed mutagenesis kit (Stratagene) using
the primers 5
 
9
 
-CGTCGCTGGAGAACCCGATCGTG-3
 
9
 
 (N)
or 5
 
9
 
-CGTCGCTGGAGAAGCCGATCGTG-3
 
9
 
 (K) according
to the manufacturer’s protocol. The mutated rLACK proteins
were sequenced to confirm their identities and cloned using
the XbaI and HindIII sites into pET3a-
 
d
 
9. 
 
Escherichia
 
 
 
coli
 
 BL21
(DE3)plysS (Novagen) were transformed, and the expressed pro-
teins were purified using [Ni]nitrilotriacetic acid chromatography as
described (5).
 
Mice.
 
Female BALB/c, C57BL/6 (The Jackson Laboratory
or IFFA Credo), and B10.D2 mice (The Jackson Laboratory)
were housed in the University of California San Francisco or
University of Lausanne pathogen-free animal facilities and
used at 8–10 wk of age. Designated mice were thymectomized
at 5 wk of age using standard methods. LACK T cell receptor–
specific transgenic (ABLE) mice are TCR-transgenic mice that
express a V
 
b
 
4/V
 
a
 
8 TCR that recognizes a peptide epitope
comprising amino acids 156–173 from the Leishmania LACK
antigen in the context of MHC class II I-A
 
d
 
 molecules. The
generation and characterization of the ABLE mice are described
elsewhere (4). ABLE mice were backcrossed 10 generations onto
the BALB/c background and, where indicated, onto back-
crossed BALB/c TCR constant region 
 
a
 
 chain deletion mutants
(TCR-C
 
a
 
0
 
; 10) to create BALB/c ABLE TCR-C
 
a
 
0
 
 mice as de-
scribed (4).
 
Parasites and Infection. L. major
 
 strains WHOM/IR/
 
2
 
/173
(designated IR/173) and MRHO/Sv/59/P (designated LV39
were passaged and maintained as described (4, 5). Groups of 4–10
mice were infected in the hind footpads with purified metacyclic
(4 
 
3
 
 10
 
5
 
) or stationary phase (2 
 
3
 
 10
 
6
 
) promastigotes as previ-
ously described (4, 5, 11). After inoculation, disease progression
was monitored using a metric caliper to quantitate footpad size.
Animals were killed at the designated times, and the popliteal
lymph nodes were harvested for the evaluation of cell types and
cytokine production as described (5). Serum was collected termi-
nally for quantitation of IgE by ELISA as described (11), and the
footpads and spleens were used to quantitate the parasite burden
by limiting dilution (12).
 
MHC Binding Affinities.
 
I-A
 
d
 
 molecules were affinity purified
from cell lysates of A20 lymphoma cells using anti–I-A
 
d
 
 mAb
MKD-6 (American Type Culture Collection [ATCC]). Peptides
were tested for binding to I-A
 
d
 
 as measured by their capacity to
inhibit the binding of 
 
125
 
I-radiolabeled OVA
 
323–336
 
 as previously
described (13).
 
Stimulation of ABLE T Cells In Vitro.
 
Spleen and lymph nodes
were harvested from BALB/c ABLE TCR-C
 
a
 
0
 
 mice and used to
produce single-cell suspensions after disruption through a 0.75-
 
m
 
m
nylon mesh filter. Cells were washed, the red cells were lysed,
and the resulting populations of ABLE T cells and APC were dis-
tributed to duplicate wells of round-bottom microtiter plates (10
 
6
 
cells/well) in cell culture medium (RPMI 1640 with 10% heat-
inactivated FCS [Hyclone], 2 mM 
 
l
 
-glutamine, 0.1 mM sodium
pyruvate, 50 
 
m
 
M 
 
b
 
2-ME, and 100 U/ml each of penicillin and
streptomycin) with the indicated concentrations of synthetic pep-
tides in a final volume of 0.2 ml. Supernatants were harvested
after 48 h for cytokine analysis by ELISA. The wells were pulsed
at 48 h with 1 
 
m
 
Ci [
 
3
 
H]thymidine, and cell proliferation was as-
sessed 18 h later.
 
T Cell Antagonism Assay.
 
CD4
 
1
 
 T cells from BALB/c ABLE
TCR-C
 
a
 
0
 
 mice were enriched from spleen and lymph node cell
suspensions by antibody- and complement-mediated lysis of B
cells, MHC class II-, and CD8-expressing cells using mAbs J11d,
BP107, and 3155 (ATCC), respectively, and low-toxicity rabbit
and guinea pig complement (Cedarlane Labs., Ltd.). The result-
ing populations were 80% V
 
b
 
4
 
1
 
 cells, of which 35–40% were
CD4
 
1
 
 and the remainder CD4
 
2
 
CD8
 
2
 
 as previously described
(14). Irradiated spleen cell populations from BALB/c TCR-C
 
a
 
0
 
mice were used as APC. Antagonism was quantitated using the
method of DeMagistris et al. (13), with slight modifications. APC
(10
 
7
 
 cells/ml) were prepulsed with suboptimal concentrations of
the wild-type LACK peptide (0.008–0.2 
 
m
 
M as established in pre-
liminary experiments) in culture medium for 2 h at 37
 
8
 
C. The
APC were washed, irradiated, and distributed to 96-well round-
bottom microtiter plates (2 
 
3
 
 10
 
6
 
 cells/well) and further incubated
with varying concentrations of the designated peptides (0.01–100
 
m
 
M) for 2 h at 37
 
8
 
C. The plates were washed, and enriched ABLE
T cells were added using 1.6 
 
3
 
 10
 
5
 
 T cells/well in 0.2 ml medium.
After 48 h, the supernatants were collected and analyzed for cyto-
kines by ELISA. Proliferation was assessed at hour 66, after pulsing
for the final 18 h with 1 
 
m
 
Ci [
 
3
 
H]thymidine/well.
 
Immune Response in Mice Injected with rLACK Proteins.
 
Groups
of BALB/c mice were injected in the hind footpads with 5, 25,
or 50 
 
m
 
g of the designated rLACK protein or 25 
 
m
 
g chicken egg
OVA in 50 
 
m
 
l buffer. At various time points, the popliteal lymph
nodes were harvested and mRNA purified for analysis of IL-4
transcripts using a semiquantitative reverse transcriptase (RT)-PCR
assay as previously described (15). Groups of these treated control
or adult thymectomized mice were challenged either 24 h or 10,
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20, or 30 d later with either designated rLACK proteins or viable
L. major and analyzed by similar methods.
BALB/c ABLE-Ca0 mice were immunized in both footpads
with 25 mg of the purified rLACK proteins or chicken egg OVA
in 50 ml buffer and, 24 h later, the popliteal lymph nodes were
collected and single-cell suspensions prepared. Cells (2 3 105)
were analyzed by flow cytometry (FACSVantage™; Becton Dick-
inson) after incubation with a combination of fluorescein isothio-
cyanate–conjugated anti-Vb4, PE-conjugated anti-CD4, and bio-
tinylated anti-CD69 mAbs, followed by streptavidin-tricolor (all
from Caltag Labs.).
Immunization with Altered rLACK Proteins. Nonthymectomized
or adult thymectomized BALB/c mice were immunized in the
hind footpad with 25 mg purified rLACK proteins or chicken egg
OVA in 50 ml of 50 mM Tris/100 mM NaCl, pH 8.0. Mice
were infected 24 h later with the designated strains of L. major
promastigotes in the left footpad and the course of infection
monitored as described above.
Cytokine Analysis and Serum IgE Determination. IL-4 and IFN-g
were measured using sandwich ELISA with mAbs 11B11 and bio-
tinylated BVD6 for IL-4 detection and R46A2 and biotinylated
XMG1.2 for IFN-g detection as described (11). Samples were
normalized to standard recombinant controls. The limits of de-
tection in these assays were 50 pg/ml for IL-4 and 1 ng/ml for
IFN-g. Cytokine production by individual lymphocytes was
assessed by ELISPOT assay as described (11). Total serum IgE
was measured using ELISA with mAbs B.IE.3 and biotinylated
EM-95 and normalized to concurrently analyzed standards (11).
Cytokine mRNA transcript abundance was quantitated using
RT-PCR with the competitor plasmid pPQRS as described (5,
15). In brief, cDNA samples were first normalized for expression
of a constitutively expressed gene, hypoxanthine phosphoribosyl-
transferase (HPRT), and then quantitated for expression of IL-4
and IFN-g as compared with competitor pseudogene transcripts
amplified within the same reaction. The ratio of the authentic
and competitive amplicons was quantitated using densitometry.
Results
Construction of Analogue Peptides of the LACK Antigenic
Determinant. Using overlapping synthetic peptides and a
panel of T cell hybridomas generated from BALB/c mice
immunized with the recombinant protein, a single I-Ad–
restricted epitope in LACK was localized to amino acids
156–173, comprising the sequence ICFSPSLEHPIVVSG-
SWD (data not shown). Almost all hybridomas reactive to
LACK expressed a Vb4/Va8 heterodimeric TCR, although
considerable junctional diversity was apparent. The putative
CDR3 peptide contact domain, however, was generally
conserved in length and charge, with a negatively charged
QE or QD motif in the TCR b chain of each of the LACK-
reactive hybridomas (3). Similarly, hybridomas established
from the lymph node cells of infected BALB/c mice that
expressed the Vb4 TCR contained the QE motif in the
CDR3; one had a charged WD motif at the same position
(2). Such features suggested that a positively charged amino
acid within the LACK antigenic determinant represented a
critical TCR contact residue. Based on the use of histidine
and other charged residues at TCR contact points among
peptides binding to I-Ad (16), we mutated the histidine at
position 164 in the wild-type peptide (LACK) to aspara-
gine or lysine, thus creating peptides LACK-N164 and
LACK-K164, respectively.
Binding Affinities of LACK Analogue Peptides to I-Ad. The
relative affinities for MHC class II molecules by LACK and
the LACK analogues were tested by assaying their capaci-
ties to compete with an I-Ad ligand of known affinity,
chicken egg OVA peptide323–336. By this assay, each of
the LACK-derived peptides displayed binding affinities for
I-Ad in the same nanomolar range as the OVA323–336 refer-
ence peptide; if anything, they showed slightly stronger af-
finities (Table I). Substitution of H164 in the wild-type
LACK determinant by N or K did not, therefore, affect its
binding affinity for MHC class II molecules.
Analogue LACK Peptides Do Not Activate LACK-reactive
T Cells from TCR-transgenic Mice. ABLE mice express a
transgenic TCR derived from a LACK-reactive Vb4/Va8
T cell clone that is activated by the LACK156–173 peptide in
the context of I-Ad (4). These mice have been crossed to
BALB/c TCR-Ca0 mice, thus creating BALB/c ABLE
TCR-Ca0 mice. These mice express a monoclonal ab T
cell repertoire consisting exclusively of the LACK-reactive
TCR transgene and were used as a source of T cells, desig-
nated ABLE T cells. ABLE T cells proliferated in response
to the LACK wild-type peptide at low concentrations (7 nM)
but not after stimulation with the LACK-N164 or LACK-
K164 analogues, even at concentrations up to 4 mM (Fig. 1).
Although ABLE T cells generated both IFN-g and IL-4 in
culture supernatants after incubation with the LACK pep-
tide, neither cytokine was detected after incubation with
the two analogue peptides nor with the irrelevant OVA
peptide that also binds I-Ad (Fig. 1). Thus, a single amino
acid substitution at position 164 in the LACK T cell epi-
tope substantially altered reactivity of the transgenic T cells,
indicating that this amino acid position is likely to be a crit-
ical TCR contact residue.
LACK Analogue Peptides Act as TCR Antagonists In Vitro.
The LACK-derived peptides were next analyzed in an antag-
onism assay that was developed to avoid peptide competi-
tion at the level of MHC occupancy and thus allow mea-
surements of events mediated by the TCR (13). Spleen cells
from BALB/c TCR-Ca0 mice were used as APC and were
preincubated with a suboptimal concentration (0.2 mM) of
the wild-type LACK peptide. Washed and irradiated APC
were then incubated with increasing concentrations (0.1–100
mM) of the LACK analogue peptides or the OVA323–336
Table I. Affinity of LACK Analogue Peptides for I-Ad MHC 
Class II Molecules
Peptide Amino acid sequence I-Ad
nM
LACK156–173 ICFSPSLEHPIVVSGSWD 63
LACK-K164 ICFSPSLEKPIVVSGSWD 68
LACK-N164 ICFSPSLENPIVVSGSWD 100
OVA323–336 ISQAVHAAHAEINE 150
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peptide before ABLE T cells were added and assessed for
their capacity to proliferate and produce cytokines.
LACK-K164 showed dose-dependent inhibition of pro-
liferation to the wild-type peptide; 50% inhibition occurred
at a concentration of 10 mM of the analogue peptide (Fig. 2).
At similar concentrations, the peptide also inhibited IL-4
and IFN-g production. LACK-N164 inhibited the prolif-
eration of ABLE T cells only at very high concentrations
(.100 mM). The production of IL-4 was inhibited compa-
rably to the LACK-K164 peptide, but IFN-g production
was inhibited consistently less by LACK-N164 in multiple
assays. The unrelated OVA323–336 peptide displayed no in-
hibitory activity. Thus, in the presence of otherwise stimu-
latory amounts of the wild-type LACK peptide, the two an-
alogue peptides behaved as TCR antagonists. Of the TCR-
mediated functions tested, LACK-N164 preferentially in-
hibited IL-4 production by ABLE T cells, whereas the ca-
pacity to proliferate and produce IFN-g was less affected;
LACK-K164 was more global in its inhibitory capacities.
LACK Analogues Fail to Activate LACK-specific T Cells In
Vivo. The same amino acid substitutions were introduced
into the full length rLACK protein by site-directed mu-
tagenesis, creating rLACK-N164 and rLACK-K164 altered
proteins. When tested in vitro for its capacity to stimulate
ABLE T cells, the rLACK protein stimulated proliferation
and IL-4 and IFN-g production at molar concentrations
comparable to those of the wild-type LACK peptide. In
contrast, the altered rLACK proteins, as their peptide coun-
terparts, did not stimulate proliferation or measurable cyto-
kine production over a wide range of concentrations (data
not shown).
To assess the activity of the rLACK proteins in vivo,
ABLE-Ca0 mice were injected in the hind footpads with
25 mg of purified rLACK, rLACK-N164, rLACK-K164,
or OVA. After 24 h, the popliteal lymph node cells were
recovered and analyzed using flow cytometry for activa-
tion, as assessed by expression of CD69 and enlargement by
light-scattering characteristics. Inoculation of rLACK effec-
tively targeted the transgenic T cells: 80% of Vb41 cells
expressed CD69 (Fig. 3) and forward/side scattering in-
creased significantly (data not shown). The total number
of transgenic T cells actually decreased in the draining
Figure 1. Response of LACK-
specific transgenic T cells to altered
LACK peptides. Spleen cells (106)
from ABLE TCR-Ca0 mice were
incubated with increasing amounts
of the designated peptides for 48 h.
Supernatants were collected from
duplicate wells and assayed for IL-4
(center) and IFN-g (right) by ELISA.
Additional duplicate wells were
pulsed with [3H]thymidine and in-
cubated an additional 18 h before
harvesting to assess proliferation by
incorporation of radioactivity (left).
No proliferation occurred in the ab-
sence of LACK peptide. Cells from
TCR-Ca0 mice generated no signals
in these assays (not shown). Results
were comparable in four separate
experiments. d, LACK; m, LACK-
N164; j, LACK-K164; s, OVA.
Figure 2. Antagonism of LACK-
specific transgenic T cells by altered
LACK peptides. APC prepared from
BALB/c TCR-Ca0 mice were
prepulsed with 0.2 mM LACK pep-
tide for 2 h, washed and irradiated,
and distributed to wells for incuba-
tion with varying concentrations of
either the LACK-N164 (m), LACK-
K164 (j), or OVA323–336 (s) pep-
tides. After 2 h, wells were washed
and LACK-specific ABLE T cells
were added. Proliferation and cyto-
kine production were assayed as de-
scribed in the Fig. 1 legend. Results
depict the percent inhibition as com-
pared with the T cell responses to
the LACK-prepulsed APC in the
absence of added peptides. Compa-
rable results were obtained in three
independent experiments.
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lymph nodes (from 2.9 3 105 after OVA to 1.3 3 105 after
rLACK), consistent with antigen-mediated deletion as pre-
viously described in other TCR-transgenic mice (17, 18).
In contrast, Vb41 T cells collected from animals injected
with the rLACK analogues showed CD69 induction and
forward/side scattering indices that were only modestly
greater than those from cells collected from animals in-
jected with the control protein, OVA (Fig. 3). Further-
more, the total number of transgenic T cells in these mice
was not significantly different from the number of trans-
genic T cells in mice that received OVA (data not shown).
Thus, as assessed by these criteria, the rLACK analogues
did not activate ABLE T cells in vivo in a manner compa-
rable to the cognate LACK protein containing the wild-
type epitope.
LACK Analogue Proteins Block Activation of the LACK-speci-
fic Response in Wild-type Mice. Prior experiments demon-
strated that the LACK antigen induced prominent IL-4
expression in Vb4/Va8 CD41 T cells after injection into
BALB/c mice that reached levels 30–100-fold greater than
after injection of a construct with the I-Ad epitope deleted
(5). Over a 5–50 mg range of rLACK, IL-4 mRNA was
induced 100-fold, whereas no IL-4 mRNA was induced
by either the 41–amino acid LACK deletion mutant or
rLACK-K164 (Fig. 4 A and data not shown). Although a
10-fold induction of IL-4 mRNA was seen after injection
of 5 mg rLACK-N164, no IL-4 mRNA was induced after
injection of 25- or 50-mg doses. None of the LACK deriv-
atives caused induction of IFN-g mRNA under the condi-
tions used. After immunization with CFA, however, each
of the constructs, rLACK, rLACK-K164, and rLACK-N164,
was capable of inducing a proliferative response from sub-
sequently isolated popliteal lymph node CD41 T cells in
response to their respective LACK156–173 epitopes (stimula-
tion indices increased 10–18-fold; data not shown). No
proliferation was induced by any of the LACK epitopes
after immunization with the LACK deletion mutant or
OVA. The 25-mg protein dose was selected for use in sub-
sequent experiments.
To assess the capacity to alter the response of the endog-
enous LACK-reactive repertoire, mice were first injected
with 25 mg of the LACK analogue proteins and then, 24 h
later, with either the authentic LACK protein or viable
Figure 3. Activation of LACK-specific transgenic T cells in vivo by al-
tered LACK proteins. Popliteal lymph node cells were collected from
ABLE TCR-Ca0 mice that had been injected 24 h previously with 25 mg
rLACK, LACK-N164, LACK-K164, or OVA proteins. Activation of
Vb41 T cells was quantitated by the presence of the CD69 surface activa-
tion marker after gating on Vb41 T cells. Data are representative mice
from three comparable experiments.
Figure 4. LACK analogue proteins
fail to activate IL-4 mRNA in vivo.
(A) Popliteal lymph node cells were
collected 16 h after injection of 25
mg rLACK, LACK-K164, LACK-
N164, or LACKD41 with the I-Ad
epitope deleted. RNA was purified
and used to template a semiquantita-
tive RT-PCR assay for the amounts
of IL-4 transcripts. Results are ex-
pressed as the fold increase in IL-4
mRNA as compared with uninjected
mice. Results shown represent com-
parable findings from three experi-
ments. (B) BALB/c mice were in-
jected in the hind footpads with 25
mg rLACK, LACK-K164, LACK-
N164, LACKD41, or OVA (pre-
challenge) and then again 24 h later
with either 25 mg LACK antigen or
3 3 106 L. major promastigotes (chal-
lenge). After 16 h, the popliteal
lymph node cells were collected,
RNA was isolated, and the relative
IL-4 mRNA levels were determined using RT-PCR as described in Materials and Methods. Results depict fold increases in IL-4 transcripts as compared
with mice immunized with the same peptides but not challenged in the secondary experiment and are representative of three comparable experiments.
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L. major promastigotes, both shown previously to activate a
brisk IL-4 mRNA response in BALB/c CD41 T cells (5).
In three separate experiments, prior injection of either ana-
logue protein substantially decreased the subsequent activa-
tion of the IL-4 response, consistent with an alteration of
the normal Vb4/Va8 CD41 T cell response (Fig. 4 B).
Prior injection of the LACK construct with the deleted
I-Ad epitope or an unrelated I-Ad epitope (OVA) did not
affect the subsequent IL-4 response. Kinetic analysis, in which
the second injection of recombinant LACK was delayed
10, 20, or 30 d after the initial immunization, revealed that
IL-4 nonresponsiveness was maintained for 10–20 d in
mice that had been injected with the mutated LACK ana-
logues but then subsequently recovered. Recovery of IL-4
responsiveness to LACK or L. major injection was ablated
by prior thymectomy (data not shown).
Protection of Susceptible BALB/c Mice by Immunization with
LACK Analogue Proteins. Based on the capacity of LACK
analogue proteins to abrogate the early IL-4 response in
BALB/c mice, we assessed the ability of immunization to
render these mice resistant to progressive disease. Cohorts
of mice were immunized once with 25 mg of the various
recombinant proteins in the footpad and challenged 24 h
later with a lethal infectious dose of wild-type L. major pro-
mastigotes of either the IR/173 or LV39 strain.
In three separate experiments with the IR/173 parasite,
the course of disease was significantly attenuated in animals
that received rLACK-N164; no attenuation was seen in
animals that received rLACK-K164 or any of the control
proteins, including the wild-type LACK protein (Fig. 5).
Whereas animals in all of the other groups had to be killed
by week 8, mice that received rLACK-N164 controlled
disease up to 12 wk after inoculation, when the experiment
was terminated. Parasitologic control was confirmed by
limiting dilution of tissues that demonstrated a 2–4-log re-
duction in parasite numbers. Immunologic analysis revealed
a threefold reduction in the number of IL-4–producing
cells in the draining lymph nodes and in serum IgE levels,
whereas the number of IFN-g–producing cells was similar
in all groups.
Protection was more dramatic using the LV39 strain.
Similar to the results using the IR/173 strain, rLACK-
N164 but not rLACK-K164 provided lasting protection in
a subgroup of nonthymectomized mice (Fig. 6 A). The
LACK protein itself provided protection in approximately
half of both wild-type and thymectomized BALB/c mice
(Fig. 6, A and B). Strikingly, either of the altered LACK
proteins, in contrast to the LACK deletion mutant or OVA
controls, provided a complete protection in thymectomized
mice that was sustained over 100 d (Fig. 6 B). When studied
at the conclusion of these experiments, the cure phenotype
was associated with attenuation of IL-4 production and
control of parasite growth in the footpads that was entirely
concordant with the lesion phenotype (data not shown).
Discussion
L. major includes a heterogeneous group of protozoa strains
that express some 10,000 proteins from a 35.5-megabase
genome (19). Despite this complexity, the early immune
response is highly focused on a single epitope from the para-
site LACK antigen in mice that express I-Ad MHC class II
molecules. As shown here, targeting T cells that recognize
this epitope using ligands that differed by a single amino
acid from the natural epitope was capable of redirecting an
otherwise ineffective immune response with a fatal out-
come to a completely protective response with long-term
cure. The specificity of the immune intervention suggests
limited plasticity in the innate LACK-reactive repertoire in
I-Ad–bearing mice, as well as limited ability of Leishmania
parasites to mediate progressive infection in such mice in
the absence of exuberant LACK recognition.
The mechanisms underlying the dominant recognition
of the LACK epitope remain unclear. Recognition does
not seem related simply to the abundance of the LACK
protein. As compared with other parasite molecules like
the major surface protease gp 63 or the major surface gly-
colipid LPG, which are present in z5 3 105 and 3–5 3
106 molecules per organism (20, 21), respectively, LACK
was less abundantly expressed. Quantitation against recom-
binant standards showed that LACK comprised only
z0.03% of total cellular protein or z30,000 molecules per
organism (Pingel, S., and R. Locksley, unpublished data).
The LACK epitope displayed in vitro affinity for I-Ad that
was comparable with endogenously eluted I-Ad peptides
(22) and contained a centrally disposed histidine residue,
creating a charged element that has been noted in other
peptides that bind this MHC molecule. Presumably, the
dominance of the epitope must result from some conflu-
ence of stability and processing of the peptide, the efficiency
of targeting to MHC class II molecules, and/or the size of
the responding T cell repertoire (23). Equally perplexing
is the dominant nature of the Vb4/Va8 TCR response to
the I-Ad/LACK peptide complex. The convergence of the
immune response on the LACK epitope through use of a
dominant Va/Vb-paired TCR has been reported using
other immunogenic peptides (24), suggesting that other an-
tigens or adjuvant-like molecules from live parasites do not
affect this clonal affinity maturation process.
Figure 5. Course of L. major
IR/173 infection in BALB/c
mice immunized with altered
LACK ligands. Groups of 5–10
mice were inoculated in the hind
footpads with 25 mg rLACK
(n), LACK-K164 (d), LACK-
N164 (h), OVA (r), or vehicle
control (j). The next day, ani-
mals were infected with L. major
IR/173 metacyclic promasti-
gotes, and the course of infection
was followed by quantitating the
size of the local lesions using a
metric caliper. Mice were killed at the final time point and analyzed for
tissue parasite burdens, the lymphocyte cytokine response, and serum IgE
as described in Materials and Methods.
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Earlier studies reported the ability to vaccinate suscepti-
ble BALB/c mice against L. major using LACK antigen ad-
ministered in a manner such that LACK-specific Th1 cells
were generated (3, 25). Indeed, LACK-specific Th1 cells were
alone sufficient to establish substantial control over infection
with L. major, demonstrating that immunoreactive LACK
peptide is expressed in vivo at physiologically important
levels (4). Despite the capacity of LACK-specific T cells to
control infection with the parasite in vivo, such T cells are
not required. Thus, BALB/c mice rendered deficient in
CD41 T cells that recognize this dominant epitope, either
through thymic expression and central deletion or by su-
perantigen-mediated deletion of all Vb41CD41 T cells,
were capable of containing L. major infection (3, 5). These
experiments suggested that LACK recognition was required
for establishing the susceptible state of BALB/c mice, al-
though neither method directly targeted epitope-specific T
cells. Thus, overexpression of LACK antigen in the thymus
might affect the T cell repertoire in ways other than dele-
tion of LACK-reactive T cells. Similarly, deletion of all Vb41
CD41 T cells targets cells of additional specificities but un-
known contributions to defense against Leishmania.
The ability of peptide ligands that differed at a single
amino acid residue to affect the subsequent course of dis-
Figure 6. Course of L. major LV39
infection in BALB/c mice immunized
with altered LACK ligands. (A) Groups
of eight nonthymectomized BALB/c
mice (j) were immunized in the hind
footpads with either vehicle control or
25 mg recombinant LACK, LACK-
K164, LACK-N164, LACKD41, or
OVA. Mice were infected in one foot-
pad the following day with L. major
LV39 stationary phase promastigotes and
the size of the local lesion quantitated as
infected minus noninfected footpads us-
ing a metric caliper. A cohort of age-
matched, resistant C57BL/6 mice was
included as shown (n). Subgroups of
resistant and susceptible mice occurred
after immunization with LACK and
LACK-N164. Results were comparable
in two independent infections. (B)
Groups of 7–8 BALB/c mice were
thymectomized (n) at 8 wk of age and
immunized and infected with L. major
LV39 promastigotes as above. Control
adult thymectomized BALB/c mice
(BALB/c ATx) remained as susceptible
as nonthymectomized BALB/c mice
(j), as shown in the first panel. Sub-
groups of resistant and susceptible mice
occurred after immunization with
LACK. Results were comparable in two
independent infections.
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ease in susceptible BALB/c mice argues strongly for highly
conserved specificity to the Th2-mediating repertoire. Al-
tered ligands are presumed to anergize or functionally alter
discrete populations of T cells by their ability to establish
incomplete signaling through the TCR complex (reviewed
in 26). Modulation of cytokine patterns by altered ligands
has been previously demonstrated (27), although applica-
tion of this technology to an acute infectious process has
been infrequently examined. Redirection of Th subset dif-
ferentiation, or immune deviation, has been reported by ei-
ther variations in antigen dose (28, 29) or through use of
altered peptide ligands (30). For a variety of reasons, we
consider it unlikely that immune deviation can account for
the protection mediated by the altered LACK proteins.
First, over a wide dose range, the LACK peptide caused no
shift in the production of IL-4 and IFN-g relative to each
other by the TCR-transgenic ABLE T cells. Second, the
altered LACK peptides induced neither proliferation nor
cytokine production by ABLE T cells. Third, the massive
activation of ABLE T cells after injection of LACK was ab-
sent after injection of the altered LACK antigens. Finally,
injections of lower doses of LACK or the altered LACK
proteins into BALB/c mice did not induce early produc-
tion of IFN-g, rather than IL-4, mRNA. We could, there-
fore, find no evidence for the establishment of a LACK-
specific Th1 response that could account for the protection
mediated by the altered LACK analogues.
More likely, protection of susceptible mice was accom-
plished through tolerance or deletion of LACK-reactive
T cells, a mechanism consistent with previous experimental
findings (5, 7). Both altered LACK proteins antagonized
IL-4 production by transgenic T cells in response to LACK.
When used to immunize BALB/c mice, they abrogated the
early IL-4 response to L. major parasites. Treated mice were
able to control parasite multiplication of the LV39 strain up
to 5 wk; over prolonged periods, and with both the LV39
and IR/173 strains, mice pretreated with the rLACK-N164
protein demonstrated persistent immunity. Thymectomized
BALB/c mice immunized with either rLACK-N164 or
rLACK-K164 were completely protected, a finding consis-
tent with the ability of the altered LACK proteins to abro-
gate IL-4 production by Vb4/Va8 CD41 T cells in these
mice. Presumably, the delayed yet progressive disease in non-
thymectomized LV39-infected mice was dependent on new
thymic emigrants. Immunization with the LACK protein
itself conferred protection to some mice. As demonstrated
using the TCR-transgenic mice, this presumably relates to
the capacity of the cognate ligand to mediate peripheral de-
letion of high-affinity LACK-specific T cells. The observed
differences in the overall grade of protection between the
two strains of L. major were surprising, but such differences
in virulence have been previously described (31, 32), as have
subset responses within cohorts of identically treated mice,
as seen here among rLACK- and rLACK-N164–treated
mice (33–35). Boosting or otherwise optimizing the immu-
nization schedule might have enhanced protection against
the IR/173 strain. The rLACK-N164 ligand, however,
conferred protection against both L. major strains, suggest-
ing that identification of dominant antigens from pathogens
can be used to target disease-producing T cells in a highly
sequence-specific manner.
Previous studies have documented that different T cell
clonotypes can respond to the same antigen within a given
T cell repertoire. Furthermore, considerable cross-reactivity
is an essential feature of the T cell receptor, which assures
that pathogenic peptides are efficiently recognized (36). Our
results suggest that the endogenous LACK-specific reper-
toire is highly constrained in its CDR3 recognition domain.
Limited plasticity of the endogenous T cell repertoire has
been previously noted with certain peptide antigens (37),
suggesting that infectious diseases may have contributed to
the evolutionary divergence of V region genes. Expression
of dominant epitopes by parasites, together with the di-
versity and size of the responding host T cell repertoire,
might greatly affect the outcome of such infections and
thus contribute to the highly diverse clinical manifestations
of leishmaniasis in human populations.
L. major contains two LACK genes expressed in tandem
from the same chromosome. Apart from what is known re-
garding their mammalian homologues, little is known re-
garding the biochemical action of these proteins. Aside
from the potential vaccine use of this antigen (3, 25), addi-
tional study promises to shed much light on the coevolu-
tion of host and parasite within the context of the immune
system, MHC recognition, and the T cell repertoire. Such
studies may have great implications for our understanding
of the basis for susceptibility and resistance to infectious dis-
eases.
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